It is unknown what next-step strategies are being used in clinical practice for patients with obsessive–compulsive disorder (OCD) who do not respond to first-line treatment. As part of a cross-sectional study of OCD, treatment and symptom information was collected.
Method:
Consecutive OCD out-patients in nine international centers were evaluated by self-report measures and clinical/structured interviews. OCD symptom severity was evaluated by the Yale Brown Obsessive Compulsive Scale (YBOCS) and Clinical Global Impression–Severity Scale (CGI-S). Clinical response to current treatment was evaluated by the CGI-Improvement Scale (CGI-I ≤ 2).
Results:
In total, 361 participants reported taking medication; 77.6% were taking a selective serotonin reuptake inhibitor; 50% reported use of at least one augmentation strategy. Antipsychotics were most often prescribed as augmenters (30.3%), followed by benzodiazepines (24.9%) and antidepressants (21.9%). No differences in OCD symptom severity were found between patients taking different classes of augmentation agents.
Conclusions:
Results from this international cross-sectional study indicate that current OCD treatment is in line with evidence-based treatment guidelines. Although augmentation strategies are widely used, no significant differences in OCD symptom severity were found between monotherapy and augmentation or between different therapeutic agents.
AbramowitzJS (1997) Effectiveness of psychological and pharmacological treatments for obsessive-compulsive disorder: A quantitative review. J Consult Clin Psychol65: 44–52.
AfsharHRoohafzaHMohammad-BeigiH. (2012) N-Acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: A randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol32: 797–803.
4.
BaerLJenikeMA (1992) Personality disorders in obsessive compulsive disorder. Psychiatr Clin N Am15: 803–808.
5.
BaldwinDSAndersonIMNuttDJ. (2005) Evidence-based guidelines for the pharmacological treatment of anxiety disorders: Recommendations from the British Association for Psychopharmacology. J Psychopharmacol19: 567–596.
6.
BandelowBZoharJHollanderE. (2008) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. World J Biol Psychiatry9: 248–312.
7.
BerlinHAKoranLMJenikeMA. (2011) Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry72: 716–721.
8.
BlochMHMcGuireJLanderos-WeisenbergerA. (2010) Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder. Mol Psychiatry15: 850–855.
9.
BlochMHLanderos-WeisenbergerAKelmendiB. (2006) A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry11: 622–632.
10.
BobesJGonzalezMPBascaranMT. (2001) Quality of life and disability in patients with obsessive-compulsive disorder. Eur Psychiatry16: 239–245.
11.
BogettoFAlbertUMainaG (2002) Sertraline treatment of obsessive-compulsive disorder: Efficacy and tolerability of a rapid titration regimen. Eur Neuropsychopharmacol12: 181–186.
12.
Canadian Psychiatric Association (2006) Clinical practice guidelines management of anxiety disorders. C J Psychiatry51Suppl 2: 9S-91S.
13.
CarrascoJLHollanderESchneierFR. (1992) Treatment outcome of obsessive compulsive disorder with comorbid social phobia. J Clin Psychiatry53: 387–391.
14.
CoricVTaskiranSPittengerC. (2005) Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial. Biol Psychiatry58: 424–428.
15.
DenysDBurgerHvan MegenH. (2003) A score for predicting response to pharmacotherapy in obsessive-compulsive disorder. Int Clin Psychopharmacol18: 315–322.
16.
duc ToitPLvan KradenburgJNiehausD. (2001) Comparison of obsessive-compulsive disorder patients with and without comorbid putative obsessive-compulsive spectrum disorders using a structured clinical interview. Compr Psychiatry42: 291–300.
17.
EisenJLManceboMAPintoA. (2006) Impact of obsessive-compulsive disorder on quality of life. Compr Psychiatry47: 270–275.
18.
FinebergNReghunandananSBrownA. (2013) Pharmacotherapy of obsessive-compulsive disorder: Evidence-based treatment and beyond. Aus NZ J Psychiatry47: 121–141.
19.
FinebergNACraigKJ (2007) Pharmacological treatment for obsessive–compulsive disorder. Psychiatry6: 234–239.
20.
FinebergNAGaleTM (2005) Evidence-based pharmacotherapy of obsessive-compulsive disorder. In J Neuropsychopharmacol8: 107–129.
21.
FoaEBLiebowitzMRKozakMJ. (2005) Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. Am J Psychiatry162: 151–161.
22.
FoaEBSimpsonHBLiebowitzMR. (2013) Six-month follow-up of a randomized controlled trial augmenting serotonin reuptake inhibitor treatment with exposure and ritual prevention for obsessive-compulsive disorder. J Clin Psychiatry74: 464–469.
23.
GhaleihaAEntezariNModabberniaA. (2013) Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study. J Psychiatr Res47: 175–180.
24.
GoodmanWKPriceLHRasmussenSA. (1989) The Yale-Brown obsessive compulsive scale: I. Development, use, and reliability. Arch Gen Psychiatry46: 1006.
25.
GuyW (1976) ECDEU Assessment Manual for Psychopharmacology - Revised. Rockville, MD: US Department of Health.
26.
HollanderEKoranLMGoodmanWK. (2003) A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder. J Clin Psychiatry64: 640–647.
KoranLM (2000) Quality of life in obsessive-compulsive disorder. Psychiatr Clin N Am23: 509–517.
30.
KoranLMHannaGLHollanderE. (2007) Practice guideline for the treatment of patients with obsessive-compulsive disorder. Am J Psychiatry164(7 Suppl): 5–53.
31.
McDougleCJGoodmanWKLeckmanJF. (1993) The efficacy of fluvoxamine in obsessive-compulsive disorder: Effects of comorbid chronic tic disorder. J Clin Psychopharmacol13: 354–358.
32.
MontgomerySAAsbergM (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry134: 382–389.
33.
MowlaAKhajeianAMSahraianA. (2010) Topiramate augmentation in resistant OCD: A double-blind placebo-controlled clinical trial. CNS Spectr15: 613–617.
34.
National Center for Biotechnology Information (2012) PubMed Drug & Supplements Monograph Citalopram.
35.
NinanPTKoranLMKievA. (2006) High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: A multicenter double-blind trial. J Clin Psychiatry67: 15–22.
36.
PallantiSHollanderEGoodmanWK (2004) A qualitative analysis of nonresponse: Management of treatment-refractory obsessive-compulsive disorder. J Clin Psychiatry65(Suppl 14): 6–10.
37.
PampaloniISivakumaranTHawleyC. (2010) High-dose selective serotonin reuptake inhibitors in OCD: A systematic retrospective case notes survey. J Psychopharmacol24: 1439–1445.
38.
RapaportMHClaryCFayyadR. (2005) Quality-of-life impairment in depressive and anxiety disorders. Am J Psychiatry162: 1171–1178.
39.
Rosa-AlcazarAISanchez-MecaJGomez-ConesaA. (2008) Psychological treatment of obsessive-compulsive disorder: A meta-analysis. Clin Psychol Rev28: 1310–1325.
40.
Rosario-CamposMMiguelEQuatranoS. (2006) The Dimensional Yale–Brown Obsessive–Compulsive Scale (DY-BOCS): An instrument for assessing obsessive–compulsive symptom dimensions. Mol Psychiatry11: 495–504.
41.
RubioGJimenez-ArrieroMAMartinez-GrasI. (2006) The effects of topiramate adjunctive treatment added to antidepressants in patients with resistant obsessive-compulsive disorder. J Clin Psychopharmacol26: 341–344.
42.
SheehanDV (1983) The Anxiety Disease. New York: Scribner.
43.
SheehanDVLecrubierYSheehanKH. (1998) The Mini-International Neuropsychiatric Interview (MINI): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry59: 22–33.
44.
SimpsonHBHuppertJDPetkovaE. (2006) Response versus remission in obsessive compulsive disorder. J Clin Psychiatry67: 269–276.
45.
SkapinakisPPapatheodorouTMavreasV (2007) Antipsychotic augmentation of serotonergic antidepressants in treatment-resistant obsessive-compulsive disorder: A meta-analysis of the randomized controlled trials. Eur Neuropsychopharmacol17: 79–93.
46.
SteinDMontgomerySKasperS. (2001) Predictors of response to pharmacotherapy with citalopram in obsessive-compulsive disorder. Int Clin Psychopharmacol16: 357–361.
47.
SteinDJKoenNFinebergN. (2012) A 2012 evidence-based algorithm for the pharmacotherapy for obsessive-compulsive disorder. Curr Psychiatry Rep14: 211–219.
48.
SteinerMGergelIWheadonD (1996) Predictors of Response to Paroxetine Therapy in OCD. In: Annual Meeting of the American Psychiatric Association, New York.
49.
Van AmeringenMManciniCPattersonB. (2006) Topiramate augmentation in treatment-resistant obsessive-compulsive disorder: A retrospective, open-label case series. Depress Anxiety23: 1–5.
50.
Van BalkomAvan OppenPVermeulenA. (1994) A meta-analysis on the treatment of obsessive-compulsive disorder: A comparison of antidepressants, behaviour, and cognitive therapy. Clin Psychol Rev14: 359–381.
